Targeting AML-associated FLT3 mutations with a type I kinase inhibitor

Tyrosine kinase domain (TKD) mutations contribute to acquired resistance to FMS-like tyrosine kinase 3 (FLT3) inhibitors used to treat FLT3-mutant acute myeloid leukemia (AML). We report a cocrystal structure of FLT3 with a type I inhibitor, NCGC1481, that retained potent binding and activity agains...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Invest
Egile Nagusiak: Jones, LaQuita M., Melgar, Katelyn, Bolanos, Lyndsey, Hueneman, Kathleen, Walker, Morgan M., Jiang, Jian-Kang, Wilson, Kelli M., Zhang, Xiaohu, Shen, Jian, Jiang, Fan, Sutter, Patrick, Wang, Amy, Xu, Xin, Tawa, Gregory J., Hoyt, Scott B., Wunderlich, Mark, O’Brien, Eric, Perentesis, John P., Starczynowski, Daniel T., Thomas, Craig J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Clinical Investigation 2020
Gaiak:
Concise Communication
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7108888/
https://ncbi.nlm.nih.gov/pubmed/32149729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI127907
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak